Stock Price Quote

CIPLA LTD.

NSE : CIPLABSE : 500087ISIN CODE : INE059A01026Industry : Pharmaceuticals & DrugsHouse : Cipla
BSE1403.904.55 (+0.33 %)
PREV CLOSE ( ) 1399.35
OPEN PRICE ( ) 1409.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 6356
TODAY'S LOW / HIGH ( )1398.85 1409.95
52 WK LOW / HIGH ( )913.2 1519
NSE1404.055 (+0.36 %)
PREV CLOSE( ) 1399.05
OPEN PRICE ( ) 1403.90
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1404.05 (238)
VOLUME 60540
TODAY'S LOW / HIGH( ) 1400.25 1407.30
52 WK LOW / HIGH ( )913 1519
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 17-08 1935
Management Info
Y K Hamied - Chairman Umang Vohra - Managing Director
Registered Office

Address Cipla House, Peninsula Business Park,Ganpatrao Kadam Marg,Lower Parel,
Mumbai,
Maharashtra-400013

Phone 022-24826000

Email contactus@cipla.com

Website www.cipla.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, Luxembourg, MCX

NEWS

16May Cipla inks pact to make additional inv
Cipla has signed definitive agreements for further investment of up to R..
15May Exide Industries, Infosys and Jindal S
Exide Industries has invested Rs 74.99 crore by way of subscription in t..
15May Cipla informs about clarification
Cipla has submitted the following clarification with respect to sale of..
15May Cipla’s promoters sell 2.53% stake in
Cipla’s promoters have sold a 2.53 per cent stake in the company for the..
13May Cipla zooms on reporting 79% rise in Q
Cipla is currently trading at Rs. 1414.00, up by 74.55 points or 5.57% f..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit1038440772.5
Gross Profit 12242.4 49469.7
Operating Profit 1366555548.1
Net Sales 40366.6165743.4

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  26643.70 (0.58%)
M.Cap ( in Cr)56616.00
Pfizer (BSE)
peergroup  4473.85 (1.59%)
M.Cap ( in Cr)20466.85
Glaxosmithkline Phar (BSE)
peergroup  2355.75 (2.80%)
M.Cap ( in Cr)39907.83
Concord Biotech (BSE)
peergroup  1494.85 (4.43%)
M.Cap ( in Cr)15638.55
Zydus Lifesciences (BSE)
peergroup  1104.45 (5.00%)
M.Cap ( in Cr)111133.51

Shareholding Pattern

FI/BANKS/INSURANCE 5.49%
PROMOTERS 33.47%
MUTUAL FUNDS/UTI 16.83%
NON-INSTITUTION 16.36%
GOVERNMENT 0%
FII 0%

About Cipla Ltd.

Cipla Ltd. was incorporated in the year 1935. Its today's share price is 1403.9. Its current market capitalisation stands at Rs 113357.31 Cr. In the latest quarter, company has reported Gross Sales of Rs. 165035.7 Cr and Total Income of Rs.162551.7 Cr. The company's management includes Rajendra Chopra, Mandar Purushottam Vaidya, Robert Stewart, PR Ramesh, Punita Lal, Ashok Sinha, Adil Zainulbhai, S Radhakrishnan, Umang Vohra, Samina Hamied, MK Hamied, Y K Hamied.

It is listed on the BSE with a BSE Code of 500087 , NSE with an NSE Symbol of CIPLA and ISIN of INE059A01026. It's Registered office is at Cipla House, Peninsula Business Park,Ganpatrao Kadam Marg,Lower ParelMumbai-400013, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are RGN Price & Co, RS Bharucha & Co, V Sankar Aiyar & Co, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.